BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17609160)

  • 1. SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells.
    Luo XG; Ding Y; Zhou QF; Ye L; Wang SZ; Xi T
    J Biosci Bioeng; 2007 May; 103(5):444-50. PubMed ID: 17609160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells.
    Luo XG; Xi T; Guo S; Liu ZP; Wang N; Jiang Y; Zhang TC
    IUBMB Life; 2009 Jun; 61(6):679-84. PubMed ID: 19472189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
    Luo XG; Zou JN; Wang SZ; Zhang TC; Xi T
    IUBMB Life; 2010 Mar; 62(3):194-9. PubMed ID: 20039369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
    Zou JN; Wang SZ; Yang JS; Luo XG; Xie JH; Xi T
    Cancer Lett; 2009 Jul; 280(1):78-85. PubMed ID: 19321255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor decreases sensitivity to chemotherapeutic agents and stimulates cell adhesion, invasion, and migration.
    Meng Q; Mason JM; Porti D; Goldberg ID; Rosen EM; Fan S
    Biochem Biophys Res Commun; 2000 Aug; 274(3):772-9. PubMed ID: 10924353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
    Kunizaki M; Hamamoto R; Silva FP; Yamaguchi K; Nagayasu T; Shibuya M; Nakamura Y; Furukawa Y
    Cancer Res; 2007 Nov; 67(22):10759-65. PubMed ID: 18006819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMYD3-NY, a novel SMYD3 mRNA transcript variant, may have a role in human spermatogenesis.
    Zhou Z; Ren X; Huang X; Lu L; Xu M; Yin L; Li J; Sha J
    Ann Clin Lab Sci; 2005; 35(3):270-7. PubMed ID: 16081583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells.
    Silva FP; Hamamoto R; Kunizaki M; Tsuge M; Nakamura Y; Furukawa Y
    Oncogene; 2008 Apr; 27(19):2686-92. PubMed ID: 17998933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
    Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
    Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
    Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
    Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity.
    Dai B; Wan W; Zhang P; Zhang Y; Pan C; Meng G; Xiao X; Wu Z; Jia W; Zhang J; Zhang L
    Oncol Rep; 2015 Nov; 34(5):2722-30. PubMed ID: 26328527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased serum dependence in the growth of NIH3T3 cells from the overexpression of human nuclear receptor-binding SET-domain-containing protein 1 (NSD1) or fission yeast su(var)3-9, enhancer-of-zeste, trithorax 2 (SET2).
    Yamada-Okabe T; Matsumoto N
    Cell Biochem Funct; 2008; 26(2):146-50. PubMed ID: 17437319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells.
    Ren TN; Wang JS; He YM; Xu CL; Wang SZ; Xi T
    Med Oncol; 2011 Dec; 28 Suppl 1():S91-8. PubMed ID: 20957523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
    Luo XG; Zhang CL; Zhao WW; Liu ZP; Liu L; Mu A; Guo S; Wang N; Zhou H; Zhang TC
    Cancer Lett; 2014 Mar; 344(1):129-137. PubMed ID: 24189459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism.
    Chalkiadaki G; Nikitovic D; Berdiaki A; Sifaki M; Krasagakis K; Katonis P; Karamanos NK; Tzanakakis GN
    Int J Biochem Cell Biol; 2009 Jun; 41(6):1323-31. PubMed ID: 19110070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration.
    Strik HM; Schmidt K; Lingor P; Tönges L; Kugler W; Nitsche M; Rabinovich GA; Bähr M
    Oncol Rep; 2007 Aug; 18(2):483-8. PubMed ID: 17611674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis.
    Yee AJ; Akens M; Yang BL; Finkelstein J; Zheng PS; Deng Z; Yang B
    Breast Cancer Res; 2007; 9(4):R47. PubMed ID: 17662123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin beta1-mediated signaling is involved in transforming growth factor-beta2-promoted migration in human lens epithelial cells.
    Yao K; Tan J; Ye P; Wang K; Xu W; ShenTu X; Tang X
    Mol Vis; 2007 Sep; 13():1769-76. PubMed ID: 17960115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells.
    Lindberg K; Ström A; Lock JG; Gustafsson JA; Haldosén LA; Helguero LA
    J Cell Physiol; 2010 Jan; 222(1):156-67. PubMed ID: 19780039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
    Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
    Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.